April 30, 2026 | There was a moment somewhere between the second and third question in a pair of investor panels at the Bioelectronic Medicine Forum this year when the tone shifted. It wasn’t a dramatic shift. No one said anything particularly controversial, but the language tightened notably. The answers got more precise and the optimism that has long defined neurotechnology didn’t disappear, it just became a little more conditional.
For years neurotechnology has been driven by the possible. What could we read from the brain? What could we write back? What entirely new categories of therapies might emerge from that interaction? That energy is still here but the conversation has evolved. The question now is not whether neurotechnology will work. It is whether anyone can build a real business around it.
At first glance the funding environment suggests caution. Founders describe a tougher landscape and early-stage capital feels harder to access but the reality, as the investors on stage made clear, is more nuanced. Capital hasn’t disappeared; it has concentrated.
“80% Of all invested dollars, funds went to 30 firms. 50% of all capital went to AI companies,” commented Jeff Chu, managing partner at Features Capital. The profound effect of that type of concentration means that the field is not shrinking but rather becoming more filtered.
The impact of such filtered investing is felt most acutely at the earliest stages. Institutional seed capital, once the entry point for new ideas, is no longer as accessible. Smaller funds are constrained, larger funds are deploying selectively, and even active investors are making only a handful of bets each year. “Star51 will make two to three investments per year,” noted Adam Rosenwach, Star51 Capital’s founding managing partner. While those two to three investments will be between $5-8 million, the implication is clear: there is still capital in the system but far fewer companies will access it and those that do will need to meet a much higher bar.
That bar has moved forward in ways that would have been difficult to imagine even just a few years ago. Early-stage investing, once defined by exploration, now looks more like pre-validation. Investors expect to see a defined mechanism of action, a clear initial indication, and increasingly early data to support both. The days of raising capital on compelling hypotheses alone are fading.
That shift is forcing founders to rethink how they tell their stories. Nowhere is that more evident than in the slow unraveling of the platform narrative. For years it was almost expected: a single technology that could address multiple indications, each larger than the last. That framing is losing credibility. “Everybody’s a platform, but you need to really nail what your first indication is before you to on to talk about being a platform,” advised Adam Caplan, founder and general partner at Jumpspace Ventures. The message is not that platforms don’t matter. It’s that they are no longer a starting point. They are something to be earned through execution.
Underlying all of this is the deeper shift in how risk is understood. A decade ago the central question in neurotechnology was technical: Could the signal be captured? Could it be interpreted? Could it be modulated in a meaningful way? Those questions haven’t disappeared but they are no longer the primary more solitary concern. Today the risk lies elsewhere.
The forces that now determine whether a company succeeds or stalls include adoption, integration, and reimbursement. A device can work perfectly and still fail if it doesn’t fit into clinical workflows, if patients don’t use it consistently, or if payers won’t cover it. In that sense neurotechnology is no longer just an engineering problem. It is a systems problem. And like any good systems problem, the solution depends as much on what surrounds the technology as on the technology itself.
Reimbursement, for example, has become a central consideration, often earlier than founders expect. “I would say it’s very, very, very important,” emphasized Jeffrey Cohen, , Landenburg Thalmann’s director of research. “Without it, commercialization becomes significantly more difficult, requiring heavier investment in sales and longer timelines to adoption.”
One positive development on the reimbursement front emerged just after the New York conference. The FDA and CMS announced the RAPID coverage pathway, designed to expedite access to certain FDA-designated Class II and Class III Breakthrough Devices for people with Medicare. Under the RAPID coverage pathway, CMS will issue a proposed national coverage determination the same day an eligible device participating in this pathway receives FDA market authorization, triggering the statutorily required 30-day public comment period. This streamlined approach could enable predictable Medicare national coverage and payment as soon as two months after market authorization, compared to approximately a year or more under the current pathway.
Distribution too has emerged as a defining factor for success. “If you don’t control distribution, it’s very hard to scale,” said Allen Gobbs, co-founder and Managing Partner of ATEM Capital. Access to patients, whether through health systems, payer networks, or home-based models, is becoming one of the most durable advantages a company can have.
Even AI and machine learning, which continue to shape the broader investment landscape, are being viewed through a more critical lens. There is little doubt that AI will play a role in neurotechnology but the question is how. “Models commoditize over time unless you have differentiated data. It’s very difficult to play in that space,” explained Caplan. In other words the value is not in the model. It’s in the data and the technology. The data is often tied directly to the devices themselves.
Consumer neurotechnology presents a different kind of tension. It is visible, well funded, and often positioned as a gateway to broader adoption but investor sentiment remains cautious. “I question the elasticity of the consumer and the clinical benefit of some products,” admitted Cohen. The concern is not that these products have no value but that their long-term economics and impact are still uncertain. And yet for all of the tightening, all of the filtering, and all of the raised expectations, the outlet for neurotechnology remains strong.
“Neuro got more investment than any other space last year,” Chu pointed out. Another investor added that investment into the category has been steadily increasing even as the broader venture market becomes more selective.
Capital is still flowing. It is just flowing differently. It is moving toward companies that are more focused, more integrated, and more aligned with the realities of healthcare delivery, which brings the field to its current moment. Neurotechnology is no longer chasing validation; it is operating under it. The science is no longer the primary question. The leading question on investors’ minds is the stability of the infrastructure, the scope of the business model, and the ability of the team driving it to navigate clinical, regulatory, and economic complexities. Fewer companies will be funded; that much is clear but those that are will be built with a level of discipline the field has not seen before. In the long run that may be exactly what neurotechnology needs.
